156 related articles for article (PubMed ID: 35501463)
1. A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.
Kim JY; Cho TM; Park JM; Park S; Park M; Nam KD; Ko D; Seo J; Kim S; Jung E; Farrand L; Nguyen CT; Hoang VH; Thanh La M; Ann J; Nam G; Park HJ; Lee J; Kim YJ; Seo JH
Oncogene; 2022 Jun; 41(23):3289-3297. PubMed ID: 35501463
[TBL] [Abstract][Full Text] [Related]
2. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
[TBL] [Abstract][Full Text] [Related]
3. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
5. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
6. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition.
Subramanian C; Grogan PT; Wang T; Bazzill J; Zuo A; White PT; Kalidindi A; Kuszynski D; Wang G; Blagg BSJ; Cohen MS
Mol Oncol; 2020 Sep; 14(9):2058-2068. PubMed ID: 32255264
[TBL] [Abstract][Full Text] [Related]
7. A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
Oh YJ; Seo YH
Oncol Rep; 2017 Oct; 38(4):2343-2350. PubMed ID: 28849241
[TBL] [Abstract][Full Text] [Related]
8. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
13. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
14. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Friedland JC; Smith DL; Sang J; Acquaviva J; He S; Zhang C; Proia DA
Invest New Drugs; 2014 Feb; 32(1):14-24. PubMed ID: 23686707
[TBL] [Abstract][Full Text] [Related]
16. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
17. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
18. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
